Zymeworks enters global license and collaboration agreement with Roche for ZW209

Zymeworks entered a global license and collaboration agreement with Roche for the research, development and commercialization of ZW209. Zymeworks is eligible for an upfront payment of $55M, a $40M payment upon initiation of the Phase 1b trial, and additional milestone payments of up to $718M.

Detected & updated continuously · Source: Nebula